ライフサイエンスコーパス: dyslipidemia

1 comorbidity (i.e. hypertension, diabetes and dyslipidemia).

2 rtension, elevated plasma glucose level, and dyslipidemia).

3 tabolic disorders like diabetes mellitus and dyslipidemia.

4 rolonging drugs, opiates, illicit drugs, and dyslipidemia.

5 or diabetes mellitus, and 51% versus 63% for dyslipidemia.

6 ciated with idiosyncratic hepatotoxicity and dyslipidemia.

7 bability for those who had both diabetes and dyslipidemia.

8 tering obesity-associated insulin resistance/dyslipidemia.

9 ng syndrome, which are associated with frank dyslipidemia.

10 n hydrolysis, improved glucose tolerance and dyslipidemia.

11 veral metabolic traits including obesity and dyslipidemia.

12 independently of hypertension, diabetes, and dyslipidemia.

13 esence of type 2 diabetes, hypertension, and dyslipidemia.

14 he development of cholestasis and associated dyslipidemia.

15 irubin, body mass index, hemoglobin A1C, and dyslipidemia.

16 ased energy intake, increased adiposity, and dyslipidemia.

17 diet-induced obesity, insulin resistance and dyslipidemia.

18 lowering of LDL-C levels or non-LDL-related dyslipidemia.

19 esistance appeared earlier than the reducing dyslipidemia.

20 n type 9 (PCSK9) are an emerging therapy for dyslipidemia.

21 cterized by insulin resistance, obesity, and dyslipidemia.

22 ressure, insulin resistance, and atherogenic dyslipidemia.

23 glucose intolerance, insulin resistance, and dyslipidemia.

24 T1D, which aggravates both hyperglycemia and dyslipidemia.

25 d that UDCA ameliorates ICP-associated fetal dyslipidemia.

26 view focused on screening for multifactorial dyslipidemia.

27 e investigated in hamsters with diet-induced dyslipidemia.

28 uch as insulin resistance, hypertension, and dyslipidemia.

29 lipase activity consistent with hallmarks of dyslipidemia.

30 m fibrate even in the absence of atherogenic dyslipidemia.

31 lin resistance, elevated blood pressure, and dyslipidemia.

32 AFLD: hyperglycemia, insulin resistance, and dyslipidemia.

33 ng therapeutic strategy for the treatment of dyslipidemia.

34 rates of childhood overweight conditions and dyslipidemia.

35 and to depend on the presence of atherogenic dyslipidemia.

36 are at higher risk of incident diabetes and dyslipidemia.

37 sion, as its overexpression or loss leads to dyslipidemia.

38 tment, in addition to those with atherogenic dyslipidemia.

39 is a target for the management of NAFLD and dyslipidemia.

40 onist approved for the treatment of diabetic dyslipidemia.

41 5 [0.44-0.67]), cardiometabolic comorbidity (dyslipidemia, 0.28 [0.22-0.37]), hypertension (0.59 [0.5

42 us (15.5%-5.9%), hypertension (29.7%-19.5%), dyslipidemia (14.0%-6.8%), and sleep apnea (9.6%-2.6%) w

43 (5 guidelines), dysglycemia (7 guidelines), dyslipidemia (2 guidelines), and hypertension (3 guideli

44 13; 95% confidence interval, 2.14-12.31) and dyslipidemia (2.35; 1.34-4.14) development.

45 n the 18- to 44-year group, smoking (56.8%), dyslipidemia (51.7%), and hypertension (49.8%) were most

46 45- to 59-year group, hypertension (59.8%), dyslipidemia (57.5%), and smoking (51.9%) were most prev

47 SIBO (65,5%), DM (70.8%), dyslipidemia (75.2%), obesity (76.6%), and metabolic syn

48 vs 0.87 [.42-1.83] per 100 person-years) and dyslipidemia (8.16 [5.42-12.27] vs 3.99 [2.67-5.95] per

49 ithout obesity who do not have hypertension, dyslipidemia, abnormal blood glucose levels, or diabetes

50 e cardiovascular risk factors (hypertension, dyslipidemia, abnormal blood glucose levels, or diabetes

51 In total, 201 schizophrenia patients with dyslipidemia after being treated with an antipsychotic w

52 ention of type 2 diabetes, hypertension, and dyslipidemia after Roux-en-Y gastric bypass.

53 Using breast cancer, dyslipidemia and Alzheimer's disease as case studies, we

54 l fatty acid oxidation, insulin sensitivity, dyslipidemia and aortic streaking in this mouse model.

55 Dyslipidemia and apolipoprotein E4 (APOE 4) allele are r

56 s a novel candidate drug target for treating dyslipidemia and associated CVD.

57 Pharmaceutical drugs targeting dyslipidemia and cardiovascular disease (CVD) may increa

58 therapeutic development for the treatment of dyslipidemia and cardiovascular disease.

59 nvincing evidence for an association between dyslipidemia and colorectal neoplasia was observed for h

60 he effects of increased bile acids, maternal dyslipidemia and deranged maternal and fetal lipid homeo

61 trategy to protect endothelial function from dyslipidemia and diabetic complications.

62 LD should be proposed in older patients with dyslipidemia and elevated ALT, even if normoweight.

63 n resistant diabetes, usually accompanied by dyslipidemia and fatty liver, as seen in lipodystrophies

64 olysis causes metabolic disorders, including dyslipidemia and hepatic steatosis.

65 esity were independently associated with the dyslipidemia and hyperglycemia criteria of MS.

66 In type 2 diabetes (T2DM), dyslipidemia and hyperglycemia damage DRG neurons and in

67 tes to the development of hepatic steatosis, dyslipidemia and hyperglycemia.

68 bile acids in the gut and are used to treat dyslipidemia and hyperphosphatemia.

69 Cardiovascular risk factors such as dyslipidemia and hypertension increase the risk for whit

70 agents and insulin), control (hyperglycemia, dyslipidemia and hypertension) and chronic microvascular

71 the lipid-lowering drug fenofibrate reverses dyslipidemia and improves insulin sensitivity in type 2

72 artery disease (CAD), presumably by causing dyslipidemia and increased atherosclerosis.

73 The contribution of dyslipidemia and inflammation in atherosclerosis is well

74 effective in improving antipsychotic-induced dyslipidemia and insulin resistance, and the effects imp

75 temically, the metabolic syndrome, including dyslipidemia and insulin resistance, occurs in the setti

76 ingxia, China to determine the prevalence of dyslipidemia and its association with body mass index (B

77 y is to evaluate the possible association of dyslipidemia and its treatment with meibomian gland (MG)

78 onoids and phenolic compounds which improves dyslipidemia and markers of systemic inflammation in pat

79 olic risk factors including hypertension and dyslipidemia and may progress to liver fibrosis.

80 tudies have suggested an association between dyslipidemia and meibomian gland dysfunction (MGD).

81 high in fat and sugar, can cause significant dyslipidemia and nonalcoholic fatty liver disease; the d

82 In atherosclerosis, this is associated with dyslipidemia and oxidative stress, but mechanisms linkin

83 increased platelet reactivity are common in dyslipidemia and oxidative stress.

84 Type 2 diabetes mellitus (T2DM), dyslipidemia and periodontitis are frequently associated

85 individuals simultaneously affected by T2DM, dyslipidemia and periodontitis, showed an altered molecu

86 rly-controlled type 2 diabetes mellitus with dyslipidemia and periodontitis.

87 titis, but systemically healthy; (DL-P) with dyslipidemia and periodontitis; (T2DMwell-DL-P) well-con

88 ell-controlled type 2 diabetes mellitus with dyslipidemia and periodontitis; and (T2DMpoorly-DL-P) po

89 the potential mechanisms related to COVID-19 dyslipidemia and propose possible adjunctive type therap

90 impairment; however, these mice also develop dyslipidemia and severe atherosclerosis.

91 Dyslipidemia and statin use have been associated with co

92 sk factors (diabetes mellitus, hypertension, dyslipidemia) and diseases (ischemic heart disease, cere

93 besity, smoking, diabetes, hypertension, and dyslipidemia), and the total number of late-life cardiac

94 of diabetes mellitus, 59% hypertension, 55% dyslipidemia, and 59% had a body mass index >/=30.

95 reased tissue and systemic oxidative stress, dyslipidemia, and an enhanced proinflammatory status of

96 syndrome, particularly abdominal adiposity, dyslipidemia, and atherogenesis.

97 sociated with increased obesity progression, dyslipidemia, and atherosclerosis in hyperlipidemic Mir1

98 ated symptoms such as obesity, hypertension, dyslipidemia, and carbohydrate intolerance, and signific

99 Incident diabetes, hypertension, dyslipidemia, and chronic kidney disease were investigat

100 ype 2 diabetes (T2D), arterial hypertension, dyslipidemia, and coronary heart disease.

101 Measures of insulin resistance, dyslipidemia, and diabetes mellitus also were associated

102 isting cardiovascular factors (hypertension, dyslipidemia, and diabetes) and preexisting cardiovascul

103 ension, diabetes mellitus, obesity, smoking, dyslipidemia, and drug abuse were analyzed in these pati

104 ncreased visceral adipose tissue, marked IR, dyslipidemia, and fatty liver.

105 y acid that attenuates inflammation, anemia, dyslipidemia, and fibrosis in vivo, potentially by bindi

106 ) reductase inhibitor (statin) treatment for dyslipidemia, and group 2, those with newly diagnosed dy

107 ronic kidney disease, diabetes mellitus, and dyslipidemia, and had more often a non-LBBB (left bundle

108 tion of sOb-R levels, increased fat mass and dyslipidemia, and hepatic steatosis in mice lacking C/EB

109 d higher in patients with diabetes, obesity, dyslipidemia, and hypertension (HR = 2.6, 95% CI = 2.3-2

110 lic drivers-abnormal adiposity, dysglycemia, dyslipidemia, and hypertension-are examined in the conte

111 onship between hypertension (HTN), diabetes, dyslipidemia, and incident severe AS requiring hospitali

112 abnormalities, including insulin resistance, dyslipidemia, and increased body mass index.

113 T1DM is accompanied by hyperglycemia, dyslipidemia, and increased inflammation in addition to

114 itrus flavonoids prevents hepatic steatosis, dyslipidemia, and insulin resistance primarily through i

115 ardiometabolic risk factors such as obesity, dyslipidemia, and insulin resistance.

116 pNaKtide not only improved steatohepatitis, dyslipidemia, and insulin sensitivity, but also ameliora

117 ndrome, including diabetes, atherosclerosis, dyslipidemia, and nonalcoholic fatty liver disease.

118 ysiologic roles in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic steatohepatitis, and thei

119 ssociated with age, male sex, increased BMI, dyslipidemia, and postoperative morbidity.

120 ystemic and hepatic insulin action, systemic dyslipidemia, and reduction of hepatic steatosis.

121 dex >50 kg/m, type 2 diabetes, hypertension, dyslipidemia, and sleep apnea were found to be significa

122 ases, such as type 2 diabetes, hypertension, dyslipidemia, and sleep apnea, are very common in the Un

123 risk associated with hypertension, diabetes, dyslipidemia, and smoking, these risk factors remain poo

124 dLDL) particles are hallmarks of atherogenic dyslipidemia, and their cholesterol content is hypothesi

125 Hypertension, obesity, dyslipidemia, and type 2 diabetes were highly prevalent

126 hey elicit the selective insulin resistance, dyslipidemia, and ultimately cell death that underlie ne

127 Obesity and dyslipidemia are hallmarks of metabolic and cardiovascul

128 at diet (HFD), we found that fatty liver and dyslipidemia are prominent early signs of liver abnormal

129 atients with type 2 diabetes who suffer from dyslipidemia, are known for their diabetogenic risk and

130 Dyslipidemia associated with triglyceride-rich lipoprote

131 s, we identified a subgroup of patients with dyslipidemia-associated autism.

132 We assessed whether 234 established dyslipidemia-associated loci modify the effects of metfo

133 ve comorbid hypertension, diabetes mellitus, dyslipidemia, atrial fibrillation, anemia, and renal dys

134 gher frequency of cardiovascular disease and dyslipidemia both before and after LT.

135 retion, have potential to effectively reduce dyslipidemia but can also lead to hepatic accumulation o

136 a is known to be associated with significant dyslipidemia, but the cause or mechanism of this metabol

137 Obesity is a major risk factor for dyslipidemia, but this relationship is highly variable.

138 where it plays a crucial role in preventing dyslipidemia by hydrolyzing triglycerides from packaged

139 Prevention and sensible management of dyslipidemia can markedly alter cardiovascular morbidity

140 The early detection and treatment of dyslipidemia can reduce cardiovascular disease risk.

141 uding insulin resistance, hyperglycemia, and dyslipidemia, can further impact tumor growth and develo

142 tifactorial disease cluster that consists of dyslipidemia, cardiovascular disease, type 2 diabetes me

143 le of ceramide-mediated signaling in hepatic dyslipidemia caused by chronic glucocorticoid exposure.

144 IDOL-induced dyslipidemia caused formation of atherosclerotic lesions

145 Diabetic dyslipidemia, characterized by increased plasma triglyce

146 osclerotic cardiovascular disease or genetic dyslipidemia; clarifying a diagnosis of metabolic syndro

147 iglycerides improved the prediction of adult dyslipidemia compared with clinical childhood risk facto

148 es improved the accuracy of predicting adult dyslipidemia compared with the approach using only child

149 g the central abnormality of the atherogenic dyslipidemia complex, the elevation of triglyceride-rich

150 n correcting most aspects of the atherogenic dyslipidemia complex, thereby preventing CVD events.

151 resulted in an epidemic of the "atherogenic dyslipidemia complex," the main features of which includ

152 nown to modify components of the atherogenic dyslipidemia complex.

153 Hyperglycemia and dyslipidemia contribute to glucolipotoxicity that leads

154 fter multivariable adjustment, hypertension, dyslipidemia, coronary artery disease, prior myocardial

155 om 0.665 when considering only risk factors (dyslipidemia, current smoking, hypertension, diabetes, a

156 ively reduced CVD in study participants with dyslipidemia, defined as triglyceride levels greater tha

157 n of type 2 diabetes mellitus, hypertension, dyslipidemia, depression, and sleep apnea, and changes i

158 ents with recent acute coronary syndrome and dyslipidemia despite intensive statin therapy, alirocuma

159 In patients with recent ACS and dyslipidemia despite intensive statin therapy, polyvascu

160 y alirocumab in patients with recent ACS and dyslipidemia despite intensive statin therapy.

161 recent acute coronary syndrome and residual dyslipidemia despite optimal statin therapy were randoml

162 kg/m(2), waist circumference, hypertension, dyslipidemia, diabetes mellitus, atrial fibrillation, an

163 diseases found among the QBB population are dyslipidemia, diabetes, hypertension, and asthma with pr

164 of CVD who have 1 or more CVD risk factors (dyslipidemia, diabetes, hypertension, or smoking) and a

165 ese among adults without known hypertension, dyslipidemia, diabetes, or impaired fasting glucose.

166 erapy; HIV-associated comorbidities, such as dyslipidemia, drug abuse, and opportunistic infections;

167 obesity, and men had a higher prevalence of dyslipidemia, drug abuse, and smoking.

168 ic hypertension, diabetes mellitus, obesity, dyslipidemia, drug dependence or tobacco use, and renal

169 These findings demonstrate an underlying dyslipidemia during the early postpartum in those GDM wo

170 tors (CVRFs; ie, diabetes, hypertension, and dyslipidemia), ethnicity, smoking, and overweight/obesit

171 ued in the long term among participants with dyslipidemia even under statin usage.

172 ty; no history of hypertension, diabetes, or dyslipidemia; family history of premature coronary arter

173 tose appears to be more lipogenic, promoting dyslipidemia, fatty liver disease, cardiovascular diseas

174 e associated with an increased risk of adult dyslipidemia for all lipids.

175 c trait, patients with both hypertension and dyslipidemia had 1.8-fold higher risk of progression to

176 ctivity and individuals who had diabetes and dyslipidemia had higher odds of receiving treatment.

177 with obesity, type 2 diabetes mellitus, and dyslipidemia has led to an emerging picture of NASH as t

178 Screening of children for multifactorial dyslipidemia has not been evaluated in randomized clinic

179 HTN, diabetes, and dyslipidemia have independent and dose-response associat

180 and accelerated thrombosis, specifically in dyslipidemia, have been mechanistically linked to the ac

181 sity, glucose intolerance, hypertension, and dyslipidemia; however, the interactions between diet and

182 Obese pregnant women have dyslipidemia; however, whether obesity impacts placental

183 etes mellitus (HR, 2.84; 95% CI, 1.92-4.19), dyslipidemia (HR, 1.48; 95% CI, 1.01-2.15), and 3 or mor

184 abetes (HR: 1.49; 95% CI: 1.44 to 1.54), and dyslipidemia (HR: 1.17; 95% CI: 1.14 to 1.21) were all s

185 robiota are associated with atherosclerosis, dyslipidemia, hypertension, and heart failure.

186 discussed concerning body fat distribution, dyslipidemia, hypertension, diabetes mellitus, inflammat

187 sk factors include physical inactivity, age, dyslipidemia, hypertension, diabetes, obesity, smoking,

188 istics, alcohol, smoking, physical activity, dyslipidemia, hypertension, menopausal status, and adipo

189 Age, sex, dyslipidemia, hypertension, smoking, and family history

190 Dyslipidemia impairs mitochondrial trafficking and funct

191 an age of 64, a baseline BMI of 27 kg m, and dyslipidemia in 10.2%), underwent esophageal cancer surg

192 in 74% (95% CI, 64 to 84), and remission of dyslipidemia in 66% (95% CI, 57 to 74).

193 sma PCSK9, and knockout of Pcsk9 ameliorates dyslipidemia in a mouse model of nephrotic syndrome.

194 e identification of those at highest risk of dyslipidemia in adulthood.

195 and harms of screening for and treatment of dyslipidemia in adults 21 years and older; the benefits

196 n screening for or treatment of asymptomatic dyslipidemia in adults aged 21 to 39 years.

197 ntary adults with abdominal obesity (75%) or dyslipidemia in an isolated workplace with a monitored p

198 e been associated with offspring obesity and dyslipidemia in childhood and adulthood, but this associ

199 Screening for dyslipidemia in childhood could delay or reduce cardiova

200 ipid levels enhances the prediction of adult dyslipidemia in comparison to childhood lipid measures.

201 mia is associated with maternal prepregnancy dyslipidemia in excess of measured lifestyle, anthropome

202 degree of adiposity, insulin resistance, and dyslipidemia in KW mice was not influenced by Nox1 delet

203 in prediabetes and diabetes correlates with dyslipidemia in man and murine models of disease.

204 pose tissue and skeletal muscle and improves dyslipidemia in mice and humans.

205 n of hepatic CB1R and iNOS improves diabetic dyslipidemia in mice with diet-induced obesity (DIO mice

206 fat mass development, insulin resistance and dyslipidemia in mice.

207 te to the pathogenesis of insulin resistance/dyslipidemia in obesity.

208 rrection of HyUA improves insulin resistance/dyslipidemia in obesity.

209 posity, inflammation, metabolic disorder and dyslipidemia in offspring fed a standard diet, suggestin

210 Dyslipidemia in pregnancy are associated with risk of ad

211 and to identify the role of hypertension and dyslipidemia in the development of the reported alterati

212 es of NASH along with improvement in ALT and dyslipidemia in the DIAMOND mice.

213 ating the potential effects of screening for dyslipidemia in this population requires extrapolation f

214 Dyslipidemia in young adults in the United States during

215 public health efforts to identify and reduce dyslipidemia in young adults prior to their childbearing

216 s and harms of screening for or treatment of dyslipidemia in younger adults remains unavailable.

217 e underlying pathophysiology of this form of dyslipidemia, in particular its association with insulin

218 eeded to determine whether statin use and/or dyslipidemia increases the risk of DED.

219 P46A1 as a potential therapeutic approach to dyslipidemia-induced retinal damage.

220 ses including obesity and metabolic disease, dyslipidemia, inflammation, atherosclerosis, hypertensio

221 le for citrus flavonoids in the treatment of dyslipidemia, insulin resistance, hepatic steatosis, obe

222 Dyslipidemia is a major modifiable risk factor for cardi

223 Dyslipidemia is an important risk factor for coronary ar

224 A history of statin use or dyslipidemia is associated with an increased odds of hav

225 Dyslipidemia is associated with greater risk of ventricu

226 Adult offspring dyslipidemia is associated with maternal prepregnancy dy

227 It is unclear whether dyslipidemia is associated with risk of colorectal neopl

228 We aimed to determine whether dyslipidemia is causally linked to CRC risk using a Mend

229 Dyslipidemia is characterized by elevated levels of circ

230 In conclusions, dyslipidemia is common in an adolescent population of No

231 Dyslipidemia is one of major risk factors for cardiovasc

232 Dyslipidemia is one of the most common adverse effects i

233 ommon metabolic disorders, like diabetes and dyslipidemia, is an important step toward precision medi

234 not influence the development of obesity and dyslipidemia, it protected mice from high-fat diet-induc

235 es, elevated blood pressure or hypertension, dyslipidemia, lack of physical activity, and unhealthy d

236 y in K/BxN mice was associated with a marked dyslipidemia, lower PON1 activity and higher bioactive l

237 Dyslipidemia, lymphoceles, and impaired wound healing we

238 ogical features, body weight, liver enzymes, dyslipidemia, markers of oxidative stress and molecular

239 ed circadian disruption and that exacerbated dyslipidemia may mediate atherosclerotic lesion formatio

240 Background: Dyslipidemia may occur in younger adults (defined as per

241 ren aged 8 to 10 years with mild to moderate dyslipidemia; mean between-group difference in TC change

242 enotype associations (>75%) was observed for dyslipidemia (n = 24), cardiomyopathy, arrhythmia, and o

243 in Subjects With HIV & Hyperlipidemia/Mixed Dyslipidemia; NCT02833844).

244 of metabolic traits (diabetes, hypertension, dyslipidemia, obesity) as additive or combined indicator

245 m have been implicated in hepatic steatosis, dyslipidemia, obesity, and insulin resistance in humans.

246 hould comorbidities (hypertension, diabetes, dyslipidemia, obesity, renal dysfunction, etc.) be treat

247 o determine the contribution of PCSK9 to the dyslipidemia of nephrotic syndrome.

248 risk factors (CVRFs; hypertension, diabetes, dyslipidemia) on long-term CVD risk in cancer survivors.

249 ved at week 24, but the effects on improving dyslipidemia only significantly occurred at the end of w

250 ssociated cardiometabolic risk factors (e.g.,dyslipidemia or hyperglycemia).

251 OR for current smoking was 1.93 (1.27-2.92), dyslipidemia OR=1.92 (1.41-2.63), and for recent abacavi

252 itional metabolic risk factor (hypertension, dyslipidemia, or diabetes) (aOR, 6.54 [95% CI, 1.87-22.8

253 nsion or elevated blood pressure, those with dyslipidemia, or those who have mixed or multiple risk f

254 Several new or emerging drugs for dyslipidemia owe their existence, in part, to human gene

255 nor tobacco consumption (P=0.001), recipient dyslipidemia (P=0.009), class II anti-human leukocyte an

256 gnosis [P < 0.001, OR 1.10 (1.07-1.14)], and dyslipidemia [P = 0.002, OR 2.14 (1.34-3.44)].

257 Although LT is associated with dyslipidemia, particularly atherogenic lipoprotein subpa

258 trol of hypertension, diabetes mellitus, and dyslipidemia persist, and further efforts are required t

259 Eatment with PItavastatin vs pravastatin for Dyslipidemia) randomised, double-blind, active-controlle

260 Data were collected from the Spanish Dyslipidemia Registry of the Spanish Atherosclerosis Soc

261 Dyslipidemia remission rates were 93.3% (28/30) for tota

262 .S. Preventive Services Task Force review on dyslipidemia screening in younger adults.

263 tion of Mecp2 causes fatty liver disease and dyslipidemia similar to HDAC3 liver-specific deletion.

264 The PSR group also had more diabetes, dyslipidemia, smoking, infarcts from small-vessel diseas

265 osclerotic CVD, as well as genetic causes of dyslipidemia (such as familial hypercholesterolemia).

266 ebo in PLHIV with hypercholesterolemia/mixed dyslipidemia taking maximally-tolerated statin therapy.

267 Outcomes included dyslipidemia (TC>/=200 mg/dL or LDL-C>/=130 mg/dL) and a

268 nd lower incidence rates of hypertension and dyslipidemia than did nonsurgery group 1 (P<0.05 for all

269 ept for gastro-esophageal reflux disease and dyslipidemia that appear to be more successfully treated

270 ity, hyperglycemia, high blood pressure, and dyslipidemia that are major drivers for the ever-increas

271 lar disease contributed to progression, with dyslipidemia the strongest modifiable risk factor.

272 .1% females] without diabetes, hypertension, dyslipidemia, the metabolic syndrome or impaired renal f

273 drome patients also show signs of peripheral dyslipidemia; thus, together these data suggest that RTT

274 IRR ranged from 1.3 (95% CI, 1.2 to 1.4) for dyslipidemia to 8.3 (95% CI, 4.6 to 14.9) for avascular

275 eir clinical practice guideline for managing dyslipidemia to reduce cardiovascular disease risk in ad

276 tory of hypertension, diabetes mellitus, and dyslipidemia; tobacco and alcohol use; and APOE epsilon4

277 to statins may enhance the effectiveness of dyslipidemia treatment in those at risk for cardiovascul

278 Atherogenic dyslipidemia (triglycerides >150 mg/dl [1.69 mmol/l] and

279 in adults, including obesity, hypertension, dyslipidemia, type 2 diabetes mellitus, psoriatic arthri

280 NASH is strongly associated with obesity, dyslipidemia, type 2 diabetes, and metabolic syndrome.

281 ars and prevalence of obesity, diabetes, and dyslipidemia was 40%, 35%, and 40%, respectively.

282 graphics and the APOE genotype, only midlife dyslipidemia was associated with amyloid deposition.

283 Resolution of dyslipidemia was higher for LRYGB than LSG at 1 year (ri

284 lop novel treatments for type 2 diabetes and dyslipidemia, we pursued inhibitors of serine palmitoyl

285 ates of hypertension, diabetes mellitus, and dyslipidemia were also assessed.

286 ostat) on obesity-induced insulin resistance/dyslipidemia were assessed.

287 Age, sex, smoking, and dyslipidemia were more strongly associated with femoral

288 <3 years, worse baseline visual acuity, and dyslipidemia were significant risk factors for failure.

289 trol of hypertension, diabetes mellitus, and dyslipidemia were similar between the sexes; however, se

290 n with maternal postpartum weight status and dyslipidemia, whereas more evidence exists for an associ

291 increased temporally except for the rate of dyslipidemia, which decreased more recently.

292 ept for gastro-esophageal reflux disease and dyslipidemia, which were more successfully treated by LR

293 for treatment of the metabolic syndrome and dyslipidemia, while avoiding systemic toxicity.

294 ents with recent acute coronary syndrome and dyslipidemia who are at VHR for recurrent ischemic event

295 ht identify younger adults with asymptomatic dyslipidemia who may benefit from lipid-lowering therapi

296 mia, and group 2, those with newly diagnosed dyslipidemia who were under lifestyle interventions.

297 Type 2 diabetes is often accompanied by dyslipidemia with elevated levels of free fatty acids (F

298 betes, 70.3% had hypertension, and 62.3% had dyslipidemia with substantial overlap among these traits

299 Both groups improved dyslipidemia, with reduced circulating triglycerides, bu

300 IDOL-induced dyslipidemia worsened albuminuria and glomerular macroph